\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesThe Commission has published the ex-post evaluation of Horizon 2020 (41% of projects are still running). The Commission has assessed a.o. the scientific, societal and economic impact of the programme with domain-specific details; the performance of the simplificaiton measures; and the Horizon 2020 leverage towards additional R&I resources. The Commission calculated that the overall success rate was on average 12%. They estimated that over 276000 peer-reviewed publications are produced, of which 3.9% are in the top 1% most cited publications worldwide. They aknowledged that there are not enough monitoring arrangements to capture wider societal impact - efforts to improve under Horizon Europe are on-going.
Interesting links:
- Commission report (12 pages)
- Exectuve summary (4 pages)
- Evaluation report (staff working document)(100 pages)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Cybersecurity
On 28 January 2026, the SECURE project has launched a first round of financial support measures to help small businesses achieve compliance with new cybersecurity requirements for their hardware and software products. This will allow micro, small and medium enterprises (MSMEs) to request co-funding to strengthen the cybersecurity of their hardware... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
